Please ensure Javascript is enabled for purposes of website accessibility

Is Now The Time to Go All-in on Clover Health Stock?

By Zhiyuan Sun - Jun 25, 2021 at 7:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clover Health has been a fantastic get-rich-quick stock in the past month. Can the party last?

Shares of Medicare Advantage health insurance company Clover Health Investments (CLOV -1.51%) are up over 98% in just one month, thanks to  as part of a short squeeze led by enthusiastic traders of the r/WallStreetBets subReddit. The stock is now holding steady at levels than when short-seller firm Hindenburg first published striking allegations in February that caused it to tank in the first place. 

On June 22, Chamath Palihapitiya, the billionaire venture capitalist behind Clover Health, publicly acknowledged that the company was the target of a short squeeze and that investors could "lose a significant portion of their investment" by buying at this time. The stock nevertheless surged over 10% on the day of the news release. So should investors stake all their chips in this buying frenzy? 

Senior couple talking to medical professional.

Image source: Getty Images.

What's the outlook?

In Q1 2021, Clover grew its revenue by 21% year over year to $200.3 million as its membership count increased by 18% over the same period to 66,300. Simultaneously, its net loss increased from $28.2 million in Q1 2020 to $48.4 million, mainly due to increased expenses in caring for patients impacted by COVID-19. It anticipates its revenue will amount to $820 million for the full year, representing a 22% increase from 2020.

The numbers here don't look that awe-inspiring, but they are rather solid in context. Clover Health's revenue growth is currently the best in the industry, well above that of health insurance giants such as Aetna, Cigna, and Humana

The secret sauce behind Clover Health is simple; spend more money on helping patients instead of banking profits. Medicare Advantage organizations are required by law to spend 85% of the federal premiums they receive on patients' health expenses. Hence, it should be no surprise that many health insurance firms (if not all) just pay out the bare minimum. On the other hand, Clover Health pays out 96% to 108% of its revenue in medical care expenses. 

That does bring up another problem. The company is largely successful due to providing premium health plans in a hyper-competitive market. However, it must consistently rely on paying out expenses at a loss in order to retain customers. In short, its business model has a huge sustainability problem (albeit, patients benefiting tremendously). This explains why the stock's short interest has hovered around 37% and isn't falling even after multiple squeezes.

The verdict

Right now, Clover Health stock isn't expensive at all, trading at 6.76 times revenue -- a reasonable price to pay for good revenue growth. But until it can find a way to turn a profit, it will consistently consume its $720 million in cash balance raised mostly from IPO proceeds. Don't get me wrong; Clover Health definitely has all-in potential. It's just best to wait until the healthcare company can generate positive net income first. That will also catalyze more short-sellers to begin covering their positions, leading to a much better risk-reward profile than where it's at now.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
CLOV
$3.25 (-1.51%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.